This study evaluates the Safety, Tolerability, Pharmacokinetics, and Anti-tumor Activity of SCC244 in patients with advanced solid tumors with c-Met Alterations.
Name: Glumetinib for tablet
Description: To evaluate the DLT in patients with advanced solid tumor
Measure: DLT(Dose limit toxity) Time: 35 daysDescription: To evaluate the MTD in patients with advanced solid tumor
Measure: MTD(Max tolerance does) Time: 35 daysDescription: To evaluate the BED in patients with advanced solid tumor
Measure: BED(Biological effective dose) Time: 35 daysDescription: To evaluate the ORR in patients with advanced solid tumor in Ib
Measure: ORR(Objective response rate) Time: 8 weeksAllocation: N/A
Single Group Assignment
There is one SNP
No EGFR T790M mutation for subjects with c-Met gene amplification or c-Met protein overexpression; KRAS/ALK/ROS1 WT or unknown mutation/rearrangement status for subjects with c-Met exon 14 skipping mutation. --- T790M ---
4. Presence of EGFR T790M mutation in NSCLC subjects pretreated with an EGFR-TKI; Known KRAS/ALK/ROS1 mutation/rearrangement in NSCLC subjects with c-Met exon 14 skipping mutation. --- T790M ---